Switch From Tysabri to Moderate-efficacy DMTs Linked to Worse Disability

Switch From Tysabri to Moderate-efficacy DMTs Linked to Worse Disability

287471

Switch From Tysabri to Moderate-efficacy DMTs Linked to Worse Disability

Patients with multiple sclerosis (MS) switching from Tysabri (natalizumab) to moderate-efficacy disease-modifying therapies (DMTs) are at a higher risk of showing signs of MS activity and experiencing disability progression than those switching to high-efficacy DMTs, a real-world study found. Based on these findings, the researchers are arguing that, when possible, MS patients should be started on high-efficacy DMTs when switching from Tysabri. The study, “Effect of switching from natalizumab to moderate- vs high-efficacy DMT in…

You must be logged in to read/download the full post.